subcutaneous sustained release injectables   SC Sustained Release Injectables • Published September 2017  •  Catalog no. SSR456K  •  Price US $3,850


Improved drug formulation technology and sophisticated injection devices are converging to create opportunities for sustained release dosing. The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug’s release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase.

Bar_Graph SC Sustained Release Injectables Report Brochure (Download PDF)

Blue document SC Sustained Release Injectables Report Order Form (Download PDF)


Subcutaneous Sustained Release Injectables – What You Will Learn

  • What are the marketed subcutaneous sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
  • What are the major factors driving SC sustained release injectable drug demand?
  • What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact?
  • How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry?
  • What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for SC sustained release injectable drug products?
  • In what therapeutic market segments do SC sustained release injectables compete? What is their market share today? What will it be in 2024? What is their expected growth rate?
  • What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?

Subcutaneous Sustained Release Injectables – Summary of Contents

Executive Summary

Sustained Release Injectable Market Dynamics

The Trend toward Self-Administration
Injectable Drug Formulation Technology
Innovation in Injectable Device Designs
Therapeutic Demand Drivers
Market Factors
Competitive Landscape
Risk Factors

Sustained Release – Branded Formulation Technologies

Biodegradable Polymers
Branded SR Formulation Technologies
Physical Process Control Methods

Sustained Release Injectables – Development Factors

Formulation Factors
Stability
Lyophilization
Packaging
Administration Factors

The SC Sustained Release Product Landscape

Alkaloids
Anesthetics
Antineoplastics
GnRH Agonists
Opioid Antagonists
Synthetic Peptides
Cytokines
Hormones
Antipsychotics

Development-stage SC SR Injectables

SC SR Injectables – Therapeutic Market Sector Analysis & Forecasts

Addiction
Diabetes
Infectious Disease
Hormone Deficiency
Metabolic Diseases
Neurology
Oncology
Leukemia
Lymphoma
Prostate
Pain Management
Reproductive Health

Company Profiles

 


Useful Links

Sustained Release and the Treatment of Schizophrenia